Vivesto (VIVE) investor relations material

Executive summary

• Q3 delivered positive topline results from both Paccal Vet studies; findings support further clinical development and expanded partnering discussions with Liberi Group.

• FDA granted Cantrixil Orphan Drug Designation for AML in November, supporting plans toward a human Phase I study once remaining preclinical work is complete.

Financial highlights

• Q3 2026 net sales were SEK 0; operating loss was SEK 6.224m versus SEK 7.136m, and net loss was SEK 6.157m versus SEK 7.191m YoY.

• Q3 EPS was SEK -0.56 versus SEK -1.34 YoY; 9M operating loss was SEK 21.639m versus SEK 25.463m, net loss SEK 21.432m versus SEK 25.005m, and EPS SEK -2.05 versus SEK -4.65.

• Q3 operating costs fell, partly reflecting lower external and personnel costs; 9M external costs were SEK 11.499m versus SEK 14.080m, and personnel costs SEK 9.429m versus SEK 9.788m.

Outlook and guidance

• Cash and short-term investments are assessed as sufficient to fund operations through Q2 2027; licensing income and additional financing remain important to longer-term funding.

• Final cat-study analyses were expected in Q4 2026; final dog-study results were expected by year-end 2026, with a registration-enabling dog study under design and regulatory dialogue planned with FDA and EMA.

• A Cantrixil pilot study in dogs is being considered, while human AML Phase I preparations depend on completion of preclinical activities and a partner to provide resources.